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Abstract
: It is projected that by 2030, 70% of all cancer related deaths Background will occur in low-middle income countries. However, data on the state of cancer in most African countries is scanty. Cancer estimates for Kenya are based on the Nairobi and Eldoret cancer registries, leaving most parts of the country unrepresented. Lacking national coverage, these data do not accurately reflect Kenya's cancer burden. The paucity of reliable data impedes formulation of effective cancer control strategies and cancer research prioritization. Here, we report the findings of a retrospective study of the cancer state in Meru County, Kenya.
: A retrospective analysis of patient files at Meru hospice was Methods carried out. 2349 cancer cases seen at the Meru hospice between 2003 and 2018 were analyzed. Data abstracted from the records included patient age, gender and cancer type. The abstracted data was analyzed by descriptive statistics.
: Our results indicate that cancer is almost evenly distributed Results across genders, with men accounting for 49% and women 51%. Stomach cancer rates are strikingly elevated and equal to those in countries with the highest stomach cancer rates globally -making it the commonest cancer in this region (14%). Among men, the most common cancers affect the prostate (18%), stomach (17%), esophagus (14%), head & neck (12%), liver (8%) and colorectum (5%). Among women, the commonest are cancers of the breast (22%), cervix (20%), stomach (11%), esophagus (8%), head & neck (6%) and liver (5%). Breast cancer occurs at a notably early age, with 20% of those affected aged below 40. Lung cancer rates are notably low in this region (1.3%) relative to world estimates.
: Cancer distribution in Meru is nearly even between sexes. Conclusion Our analysis suggests that the Meru region is a stomach cancer hotspot and that it also experiences elevated esophageal cancer levels. 1,2 2 2 2 3 4 1 1
Introduction
Accounting for over 70% of all global deaths annually, noncommunicable diseases (NCDs), including cancer, are the world's leading cause of mortality 1, 2 . The bulk of NCD global burden is borne by low and middle-income countries (LMICs), where greater that 75% of all NCD-associated deaths occur 1 . After cardiovascular complications, cancer is the second leading cause of mortality globally -causing more than 9 million deaths annually 1, 3 . In 2018, there were 18 million new cancer cases and 9.6 million cancer deaths worldwide 4 . These numbers are projected to rise to 29.5 million new cancer cases and 16.5 million cancer deaths by the year 2040 5 . Cancer is projected to be the leading cause of death worldwide within the 21 st century 4 . It is estimated that 70% of cancer deaths occur in LMICs 6,7 .
Comprehensive data on cancer incidence and mortality is sparse in most African countries 8 . Nonetheless, it is estimated that by 2030, the number of new cancer cases will rise most rapidly in Africa, with a projected 70% increase in cancer rates on the basis of demographic changes alone 8, 9 .
Cancer incidence data provided by the World Health Organization's (WHO) International Agency for Research on Cancer (IARC) are derived from population-based cancer registries (PBCRs). While PBCRs have national coverage in some countries, in many parts of the world, including Africa, they are subnational and cover a few urban areas 4 . Only 1% of Africa is covered by high-quality cancer registries 4, 10, 11 . Hence, estimates of cancer incidence and mortality in most African countries are likely to be significantly underestimated due to a range of factors including a lack of cancer registries 8 . For instance, IARC's 2018 comprehensive report on cancer in Sub-Saharan Africa (SSA) is based on 25 cancer registries in 20 countries 9 . This report's data on cancer in Kenya is based on two cancer registries; the Nairobi cancer registry and the Eldoret cancer registry 9 , which may not accurately portray the country's cancer burden. This paucity of reliable information about cancer incidence, distribution and mortality greatly limits the country's ability to develop effective cancer control and prevention programs.
Nonempirical observation indicates that the Meru region of Kenya has one of the highest cancer rates in the country 12, 13 . Here, we present data from the Meru hospice in Eastern Kenya and describe the pattern of cancer in the greater Meru region of Kenya for the period between 2003 and 2018 ( Figure 4 ). We contend that in the absence of a comprehensive cancer registry, the data we present here provide a valuable resource to guide cancer control policy and prioritize cancer research efforts. We report that for some cancer types, incidence rates in the greater Meru region markedly differ from GLOBOCAN's cancer rate estimates for Kenya, East Africa, Africa and globe.
Methods

Ethical clearance
Ethical clearance for this study, approval number 908, was obtained from the Institutional Research Ethics Committee of Of the 2349 cancer cases eligible for further examination, entries that were incomplete for particular forms of analysis were excluded from those analysis only. For instance, entries lacking the age were excluded from age-distribution analysis but included in other forms of analysis. Cancer entries whose site was not clearly recorded, e.g. those entered as SCC without indication of the affected site, were excluded from the analysis of cancer incidence by type. Statistical analysis and graphs were done using GraphPad ® Prism 6 statistical software. Analysis was done to describe cancer incidence in Meru by age, sex, type and age-distribution. Incidence refers to the number of cancer cases recorded at Meru Hospice between 2003 and 2018. Incidence is conveyed here as a proportion (%) of the total number of cases under consideration, i.e. the total male and female cases combined, total male cases only or total female cases only. For the age at diagnosis analysis, all cancer records were used except where the age was missing in the register.
Results
Cancer cases are distributed evenly between genders
To characterize the patterns of cancer distribution in the larger Meru region, Kenya, we analyzed cancer records at Meru Hospice for the years 2003 to 2018. In total, after excluding incomplete entries, cases from outside the larger Meru region and non-cancer cases, 2349 out of the 2424 cases seen at Meru Hospice from 2003 to 2018 were analyzed. Of the 2349 cancer cases, 1151 (49%) were male and 1198 (51%) were female ( Figure 1A) , indicating an about equal distribution of cancer cases across sexes 21 . The 10 most frequent cancer types in both sexes combined are shown. C) Stomach cancer, esophageal cancer, head and neck cancers and liver cancers occur more frequently in men than women. Colorectal cancer affects men slightly more frequently than women. Pancreatic and lung cancer rates are slightly higher in men than women. D) The 10 most frequent cancer types in men only are shown. E) The 10 most frequent cancer types in women only are shown. D' and E') The most common head and neck cancers types in men only and women only are shown. F.) The various head neck cancer types affect men more frequently than women.
Prevalence of cancer cases by type in both sexes
We next analyzed the distribution of cancer cases by type in both sexes. From this analysis, the 10 most frequent cancers in both sexes combined, were stomach cancer (13.76%), breast cancer (11.93%), esophageal cancer (11.03%), cervical cancer (10.23%), prostate cancer (9.51%), head & neck cancers (9.21%), liver cancer (6.54%), Colorectal cancer (4.2%), pancreatic cancer (2.76%) and lung cancer (1.32%) ( Figure 1B) . 30 male and 20 female cases lacking information on the cancer type or the affected sited and whose diagnosis was recorded only as SCC were excluded from this analysis.
Cancer distribution in men vs women
Next, we analyzed the cancer types to establish their proportions in male vs female patients. This analysis does not apply to the sex-specific cancers, i.e. prostate cancer, cervical cancer and ovarian cancer. Stomach cancer, which is the most common cancer type in this region ( Figure 1B) , was found to affect men more frequently than women, with 60% of cases occurring in men. Expectedly, our analysis revealed that breast cancer mostly affects women, with 95.7% of breast cancer cases afflicting women. Our analysis also revealed that esophageal cancer affected men more frequently than women, with 63% of cases occurring in men. Head and neck cancers are also more common in men, in whom 66% of cases occur. Likewise, liver cancer affects men more frequently than women, with 64% of cases being in men. Colorectal cancer is only slightly more frequent in men, who are affected in 54% of cases. Together, these data indicate that, as in other world regions, most cancers affect men more frequently than women 22 . The reasons for this gender bias are unclear. However, pancreatic and lung cancer appear to occur in women slightly more frequently than in men, with 55% of pancreatic and lung cancer cases affecting women ( Figure 1C ). It should also be noted that our data show that the rates of these two diseases are relatively low in the Meru region. 50 cases whose diagnosis was recorded only as SCC without indication of affected site were excluded from this analysis.
Cancer distribution by type in men and women
We next analyzed the distribution patterns of cancer types among men and women separately. To do this, the data on cancer cases diagnosed in men were first analyzed and ranked by cancer type frequency. Frequency is expressed as the percentage of a cancer type out of the total number of male or female cancer cases seen at Meru Hospice from 2003-2018. From this analysis, prostate cancer is the most frequent in men, accounting for close to 20% of all cancers in men ( Figure 1D ). It is followed by stomach cancer (17%), esophageal cancer (14%), head and neck cancers (12%), liver cancer (8%) and colorectal cancers (5%) ( Figure 1D ). Other cancer types in the top 10 most frequent cancers in men are pancreatic cancer (2.52%), bone cancer (1.3%), lung cancer (1.22%) and multiple myeloma (1.22%) ( Figure 1D ). 30 male cases recorded only as SCC and whose type/site was unknown were not analyzed. Among women, breast cancer was the most frequent cancer type, accounting for 22% of all cancer cases in women. It is followed by cervical cancer (20%), stomach cancer (11%), esophageal cancer (8%), head and neck cancers (6%) and liver cancer (5%) ( Figure 1E ). Other cancers in the top 10 most frequent cancers in women are colorectal cancer (4%), pancreatic cancer (3%), ovarian cancer (2%) and lung cancer (1.22%) ( Figure 1E ). 20 female cases recorded only as SCC and whose type/site was unknown were not analyzed. Head and neck cancer collectively refers to cancers affecting various sites in the head and neck region -including the oral cavity, nasal cavity and the pharynx 23 . To establish the incidence of specific head and neck cancers in men, we broke down the cases by site. It was found that 58% of head and neck cancers in men affect the oral cavity ( Figure 1D' ). Cancers affecting the pharynx and larynx account for 22% and 15% of all head neck cancers in men, respectively ( Figure 1D') . A similar analysis of head and neck cancer cases in women revealed that 58% of the cases affect the oral cavity, while 25% and 6% affect the pharynx and larynx, respectively ( Figure 1E '). However, the incidence of head and neck cancers is almost twice as high in men than in women ( Figure 1C ).
Age distribution of cancer in the Meru region
Next, we analyzed cancer distribution by age in both sexes together as well as separately. We first analyzed all cancer cases to establish the mean age of cancer occurrence in men and women combined. The average age of cancer diagnosis in both sexes combined is 58 years. In men and women separately, the average age of cancer diagnosis is 61 and 56 years, respectively ( Figure 2A ). We next analyzed the age of diagnosis for the top six cancer types (each responsible for ≥5% of the total cancer cases) in men. The average age of diagnosis for prostate cancer, stomach cancer, esophageal cancer, head and neck cancers, liver cancer and colorectal cancer was 72, 61, 65, 51, 55 and 60 years, respectively ( Figure 2B ). In women, the average age of diagnosis for breast cancer, cervical cancer, stomach cancer, esophageal cancer, head and neck cancers and liver cancer was 51, 55, 61, 63, 58 and 58 years, respectively ( Figure 2C ).
We then analyzed the distribution pattern of the top six cancer types (each responsible for ≥ 5% of total cancer cases) by age of diagnosis in both sexes as well as in men and women separately ( Figure 3 ). In men, cancer diagnosis peaked in age group 60-69, at which age 25% of all cancers in men were diagnosed ( Figure 3A ). 19% of all cancers in men were diagnosed in age group 50-59 and 23% were diagnosed in age group 70-79. Together, 66% of all cancers in men were diagnosed in these three decades of life ( Figure 3A ).
Next, we analyzed the age distribution of the top six cancers in men by type. The most frequently diagnosed cancer among men was prostate cancer, which accounts for 19% of cancers in men ( Figure 1D ). Analysis of the age-distribution of prostate cancers indicated that its diagnosis peaked in age group 70-79, which comprised 28% of the cases ( Figure 3A- Stomach cancer accounts for 17% of all cancers in men ( Figure 1D ). The age distribution analysis revealed that stomach cancer peaked in age group 60-69, in which 31% of the cases were diagnosed. 25% of stomach cancer cases in men were diagnosed in age group 50-59 ( Figure 3A -II), 56% were diagnosed between 50 and 69 years of age, 16% of all stomach cancer cases were diagnosed before 50 years of age ( Figure 3A -II) and 28% after the age of 70 ( Figure 3A -II).
The frequency of esophageal cancer diagnosis in men peaks in age groups 60-69 and 70-79, in which 54% of all male cases were diagnosed ( Figure 3A -III). 30% of esophageal cancers in men were diagnosed before age 60 ( Figure 3A -III) and 15% after the age of 80 ( Figure 3A -III).
Diagnosis of head and neck cancers in men peaked in age group 50-59, in which 24% of the cases were diagnosed. 37% of head and neck cancers occurred before 50 years and 16% in age group 60-69 ( Figure 3A -IV). 7% of head and neck cancers in men were diagnosed before 30 years of age and 15% past 70 years.
Liver cancer diagnosis in men peaked in age groups 50-59 (22%) and 60-69 (22%), in which 44% of liver cancers were diagnosed ( Figure 3A -V). 34% of liver cancers in men were diagnosed before the age of 50 ( Figure 3A -V) and 23% past 70 years of age.
Finally, colorectal cancer diagnosis among men peaked in age group 60-69, in which 31% of cases were diagnosed ( Figure 3A -VI). 28% of all colorectal cancers in men were diagnosed before age 50 and 31% of all colorectal cancers in men were diagnosed after 70 years of age ( Figure 3A -VI).
Age-distribution analysis revealed that cancer among women peaks a decade earlier than it does in men ( Figure 3B ). 20% of cancers diagnosed in women occur in age group 40-49, 22% in age group 50-59 and 20% in age group 60-69. Together, 62% of all diagnosed cancers in women occur in these three age groups. 34% of all cancers in women were diagnosed under the age of 50 and 23% after the age of 70.
We next analyzed the age-distribution of the top six cancers in women. The most frequently diagnosed cancer in women was breast cancer, which accounts for 22% of all diagnosed cancer cases in women ( Figure 2E ). Analysis of breast cancer age distribution indicated that its diagnosis peaked in age group 40-49 (30%) and age group 50-59 (20%), with 50% of all breast cancer in women diagnosed in these two age groups ( Figure 3B -I). 20% of all female breast cancer cases were diagnosed before 40 and 30% after age 60 ( Figure 3B -I).
Cervical cancer diagnosis peaked in age groups 40-49 (24%) and age group 50-59 (25%), with 49% of all cervical cancers diagnosed in these two decades ( Figure 3B -II). 12% of all cervical cancer cases were diagnosed before age 40 and 38% of cervical cancer cases were diagnosed after 60 years of age ( Figure 3B -II).
Stomach cancers in women peaked in age group 60-69 at 24%. 18% of all stomach cancers in women fell in age group 40-49, 19% in age group 50-59 and 20% in age group 70-79 ( Figure 3B -III). 7% of stomach cancer cases in women were diagnosed before 40 years of age ( Figure 3B -III). 14% of stomach cancer cases in women occurred after the age of 80 ( Figure 3B -III).
Diagnosis of esophageal cancer cases in women peaked in age groups 60-69 and 70-79, in which 53% of the cases were diagnosed. Of all esophageal cancer cases in women, 20% were diagnosed in age group 50-59 and 26% in age group 60-69 ( Figure 3B -IV). 13% of esophageal cancer cases were in women younger than 50 and 13% were diagnosed after 80 years of age ( Figure 3B-IV) .
Head and neck cancer diagnoses in women peaked at age groups 50-59 and 60-69, in which 52% of the cases were diagnosed ( Figure 3B -V). 25% of head and neck cancers in women occurred before 50 years of age and 23% after the age of 80 ( Figure 3B -V).
Liver cancer in women peaked in age groups 60-69 and 70-79, in which 48% of liver cancer cases were diagnosed ( Figure 3B -VI). 28% of liver cancer cases in women occurred before 50 years of age and 18% in age group 50-59. 6% of all liver cancers in women were diagnosed after the age 80 ( Figure 3B-VI) .
Five cases, one male and four female, that lacked age information were not included in the analysis of cancer distribution by age.
Rare cancer types seen at the Meru hospice Outside of the top 10 most frequent cancer types, there were various other cancer types seen at the Meru hospice during the study period. These rare cancer types (responsible for ≤1.2% of cases) include bone cancers, ovarian cancer, melanoma, multiple myeloma, leukemia, lymphoma, Kaposi sarcoma, kidney cancer and uterine cancer ( Figure 5 ).
Discussion
African countries are experiencing an increasingly heavy cancer burden 8 . This is attributable to multiple factors including lifestyle changes, aging populations and increased proliferation of cancer risk factors 24 . Despite the grim statistics, cancer in most African regions receives limited public health resources 8,25 . This is partly due to a lack of comprehensive information on the cancer burden in these countries. This deficiency hampers effective cancer control and prevention policy as well as cancer research prioritization. The most comprehensive cancer incidence and mortality reports on cancer in SSA are produced by the IARC. These reports are based on the PBCRs of the respective countries 4 . However, most African countries lack high-quality PBCRs 4,24,25 . According to volume XI of IARC's Cancer Incidence in Five Continents report, only 1% of Africa is covered by high-quality PBCRs 4, 11 . In addition, where PBCRs are available, they are often subnational and usually based on one or few major cities. For instance, IARC's 2018 report on cancer incidence in SSA is based on just 25 cancer registries from 20 countries 4, 9 . As cancer distribution may vary widely even within the same country 25-29 , reliance on few subnational PBCRs may significantly underestimate cancer incidence and distribution in these countries.
IARC's report on cancer incidence in Kenya is based on the two main cancer registries in the country; the Nairobi cancer registry and the Eldoret cancer registry. The other operational PBCR in the country is the Kisumu cancer registry, in western Kenya 30,31 . The Nairobi cancer registry consists of data from hospitals within Kenya's capital, while the Eldoret The lack of quality PBCRs with national coverage means that most parts of Kenya are unrepresented in national cancer estimates. However, most public hospitals and hospices possess low-quality cancer patient registers that can partially remedy the deficiency in PBCRs. While such registers do not meet the standards of quality PBCRs, they are unbiased indicators of cancer incidence in their respective populations. In this retrospective study, using data from the patient register at the Meru hospice, we report the state of cancer in the Meru region of Eastern Kenya. Paying greater attention to the most common cancers in this region, we discuss how our cancer incidence observations deviate from GLOBOCAN's national, regional and global cancer rate estimates.
Stomach cancer
Cancers of the stomach are responsible for almost 800,000 annual deaths worldwide 4 . According to GLOBOCAN's estimates, it is the fifth most common cancer globally, making up 5.7% of all cancers. Its incidence is reportedly highest in Eastern Asia (11% of cancers in both sexes combined) and lowest in Africa, where it constitutes only 3% of cancers in men and women combined 4, 32 . Our data show that in this region of Kenya, stomach cancer is the commonest cancer in both sexes combined, constituting 14% of all cancers. This rate is similar to its rates in countries in Eastern Asia with the highest stomach cancer incidence globally, including Japan, Republic of South Korea and Mongolia where it constitutes 13.1%, 13.4% and 14.4% of all cancers, respectively 4, 32 . From our analysis, this disease is the second most common in men, making up 17% of cancers in men and third most common in women, constituting 11% of cancers in women. These rates are markedly elevated relative to the global stomach cancer rates in men (7.2%) and women (4.1%) 32 . Together, this indicates that stomach cancer incidence is surprisingly elevated in Meru to a rate that equals stomach cancer incidence in countries with the highest rates worldwide. Interestingly, elevated stomach cancer rates were observed in this region as early as in the early 1990s 33 . Globally, stomach cancer rates are two-fold higher in men than women 4 . Consistent with this observation, our analysis shows a 1.5-fold higher stomach cancer rate in men than in women.
Helicobacter pylori (H. pylori), which infects more than 50% of the world's population, is an established major risk factor for stomach cancer [34] [35] [36] [37] 4, 45 . There is compelling evidence that obesity is an important risk factor 4,46 but the importance of body weight in SSA prostate cancer is not evident. The factors leading to high prostate cancer rates in Kenya are unknown and further investigation into its etiology is required.
Esophageal cancer
In 2018 there were close to 600,000 new esophageal cancer cases worldwide, resulting in over half a million deaths. This disease is the leading cause of cancer mortality in Kenya and the third leading cause of cancer deaths in East Africa. It is the sixth leading cause of cancer deaths worldwide 4, 32 . Our study ranks it the third most frequent cancer, making up 11% of all cancers in men and women combined. This is a markedly elevated rate relative to its global rate (3.2% incidence; seventh most common; 32 . Our data reveal a marked esophageal cancer elevation in both men (14.3% of cancers in men; third most common) and women (7.9% of cancers in women; fourth most common) when compared to the global rates of the disease in men (4.2% incidence; seventh most common) and women (2% incidence; 13 th most common) 32 seek to better characterize the genetic and non-genetic risk factors driving this disease, given that breast cancer incidence is climbing fastest in African countries 4, 60 .
Cervical cancer
In 2018, there were 570,000 new cervical cancer cases and 311,000 cervical cancer deaths worldwide. It is the fourth most common cancer among women globally, at a 6.6% incidence rate 4, 32 . The highest cervical cancer incidence and mortality rates are seen in Africa 4 . Our analysis shows that cervical cancer is strikingly elevated in women from the Meru region in relation to the disease's global estimates. Our analysis ranks this disease fourth commonest in both sexes together (10.2% of all cancers) and second most common among women (20% of cancers in women). These rates are consistent with GLO-BOCAN's estimates, which rank cervical cancer the second most common cancer in Kenyan women (18.3% of cancers in women) 32 . The vast majority of cervical cancer cases are linked to persistent infection by at least one high-risk human papillomavirus (HPV) 61,62 , mainly HPV16 or HPV18 63 . It is estimated that 9.1% of Kenyan women carry cervical HPV/16 infection and more than two thirds of invasive cervical cancers are attributable to HPV16 and/or HPV18 infection 64 . However, HPV infection alone is not sufficient to induce cervical cancer and additional risk factors influence cervical carcinogenesis 4, 65, 66 . Principal cofactors include cigarette smoking, multiparity, immunosuppression and the use of oral contraception 4,67,68 . While it is likely that majority of cervical cancers in Meru women are HPV-associated, further studies are needed to establish this. Comprehensive research is required to uncover the cofactors driving the high incidence of this disease and their roles.
Head and neck cancers
Head and neck cancer broadly refers to malignancies that affect one or more sites of the head and neck region. This region includes the oral cavity, paranasal sinuses, pharynx, larynx, thyroid, associated lymph nodes, soft tissues and bone 69 . Globally, head and neck cancers account for about 8% of all cancers in both sexes combined and about 5% of all cancer deaths 4 . Head and neck cancers disproportionately affect more men than women 70 . From our analysis, head and neck cancers are the sixth commonest cancer type, comprising 9% of all cancers in men and women combined. This group of cancers is fourth most common in men (12.4% of cancers) and fourth most common in women (7.9% of cancers). Our study shows that the rate of these cancers is twice as high in men than women and that the oral cavity is the most frequently affected site, accounting for about 60% of all head and neck cancers in men or women. Multiple factors, including HPV infection, EBV infection, cigarette smoking, high alcohol consumption, poor oral hygiene and chewing leaves from certain plants have been implicated as head and neck cancer risk factors 71-77 . Several genetic risks, including aberrations in the Notch pathway and chromatin factors 78,79 , have also been implicated in the development of head and neck cancer. Further research is needed to establish the involvement of these and other factors in the etiology of head and neck cancers in this and other Kenyan regions.
Liver cancer
In 2018, there were an estimated 841,000 new liver cancer cases worldwide and more than 780,000 liver cancer deaths. Globally, this disease ranks sixth most common in both sexes combined, making up 4.2% of all cancers, and is the fourth leading cause of cancer deaths 4, 32 . Accounting for 6.5% of all cancers in men and women combined, our analysis reveals a moderate elevation in liver cancer rates in the Meru region. Globally, liver cancer is the fifth commonest cancer in men (6.3% of cancers in men) and sixth commonest among women (2.8% of cancers in women) 32 . Relative to global rates, our analysis reveals a moderate elevation of liver cancer incidence among men (8.5% of cancers in men) and women (4.7% of cancers in women). The major risk factors for liver cancer include chronic hepatitis B or hepatitis C infection, aflatoxin ingestion and high alcohol consumption 80,81 . Given the high prevalence of these risk factors in Kenya 82-85 , they are likely to be important drivers of liver cancer in the Meru region. However, further research is necessary to establish how liver cancer incidence in Meru correlates with these and other probable risk factors.
Colorectal cancer
In 2018, there were close to 1.8 million new colorectal cancer cases worldwide and nearly 900,000 colorectal cancer deaths. Globally, colorectal cancer ranks third commonest in men and women combined (10.2% of all cancers), third most common in men (10.9% of cancers in men) and second most common in women (9.5% of cancers in women) 32 . Conforming with reports that colorectal cancer rates are low in African regions, our study reveals a much lower colorectal cancer rate than estimated globally. Our analysis ranks colorectal cancer eighth most common in men and women combined (4.2% of all cancers), sixth most common in men (4.6% of cancers in men) and seventh most common in women (3.8% of cancers in women). These rates conform with GLOBOCAN's assessment of colorectal cancer in Kenya, which estimates a 4.8% incidence in men and women combined, 5.9% incidence in men and 4.1% incidence among women 32 . However, GLOBOCAN ranks colorectal cancer the fifth most common in Kenya 32 , compared to our observation of eighth most common in the Meru region. According GLOBOCAN, colorectal cancer ranks third and fourth most common in Kenyan men and women, respectively 32 ; above its rank of sixth and seventh most common cancer in the Meru region in men and women respectively. The lower ranking of colorectal cancer in our analysis is due to elevated rates of stomach, head and neck and liver cancer. Advanced age, sedentary lifestyles, familial predisposition, cigarette smoking, heavy alcohol consumption and diet have been proposed as major colorectal cancer risk factors 4, 86 .
The roles of these and other risks in the etiology of this disease have not been investigated in Kenyan populations. Nonetheless, we observe that most colorectal cancer cases occur after the age of 50, indicating that, as in other parts of the world, advanced age may be an important risk factor. Consistent with global reports that colorectal cancer afflicts men more than women 32,87 , we observe more cases of the disease in men (54% of colorectal cases) than women (46% of colorectal cases). Comprehensive studies are warranted to establish the roles played by various risk factors in the etiology of this disease in Kenyan populations.
Pancreatic cancer
In 2018, there were over 450,000 new pancreatic cancer cases worldwide and more than 430,000 pancreatic cancer deaths 32 . Global pancreatic cancer incidence is estimated at 2.5% of cancers in both sexes combined (12 th most common), 2.6% of cancers in men (12 th most common) and at 2.5% of cancers in women (11 th most common) 32 . Consistent with global estimates, we observed that pancreatic cancer comprised 2.7% of cancers in both sexes combined (ninth most common), 2.5% of cancers in men (seventh most common) and 3% of cancers in women (eighth most common). However, these rates are about twice as high as the national pancreatic cancer estimates for Kenya. According to GLOBOCAN 2018 estimates for Kenya, pancreatic cancer makes up 1.5% of all cancers in both sexes combined (14 th most common), 1.8% of cancers in men (13 th most common) and 1.4% of cancers in women (14 th most common). The distribution of pancreatic cancer in Meru men and women is consistent with the global distribution pattern, which shows a moderately higher incidence in men than women 32 . It is thought that most pancreatic cancer cases are driven by environmental risks 88 . Suspected risk factors for this disease include advanced age, cigarette smoking, high body weight, diet, diabetes and ethnicity 88, 89 . As with most cancer types, the causes of pancreatic cancer in Kenyan populations have not been investigated. Future research will elucidate the role played by these factors in Kenyan pancreatic cancers.
Lung cancer
It is estimated that in 2018, there were about 2.1 million new lung cancer cases worldwide and close to 1.8 million lung cancer deaths 4, 32 . Globally, lung cancer is the leading cancer type in men and women combined, constituting 11.6% of all cancers. It is the leading cancer type in men, making up 14.5% of cancers in men and the third most common in women, accounting for 8.4% of cancers in women 4, 32 . Curiously, our analysis ranks lung cancer 10 th most common in men and women combined, constituting only 1.3% of all cancers. Among men it is ninth most common, making up only 1.2% of cancers in men. It is the 10 th most common cancer among women and makes up just 1.2% of cancers in women. 
General Comments
This report on the state of cancer in Meru has good intentions but its methods and conclusions are misleading. As the authors correctly noted, the lack of data hampers effective cancer control and prevention policy, as well as cancer research prioritization. It is also important to call for more concerted epidemiological and basic cancer research to guide formulation of effective cancer care and control programs. However, patient data from one hospice in Meru county do not provide information on the state of cancer in Meru.
The study data are interesting if presented appropriately as data from 2003-2018 on cancer patients admitted to the Meru Hospice serving residents of the larger Meru region in Eastern Kenya. The data could answer questions about change in hospice admissions over time, characteristics of cancer patients admitted to hospice, and could provide information for planning of hospice and cancer services in the region. These data should not be interpreted as cancer incidence observed in Meru county; they are not the appropriate data needed to support conclusions about the burden of cancer in Meru.
The computation of cancer incidence rates requires data from population-based cancer registries that capture data on all newly diagnosed cancers (numerator) among residents in a well-defined population (denominator). Hospices or hospitals do not capture information on all incident cancers diagnosed in a well-defined population. The numerator does not include all newly diagnosed cases and likely includes recurrent cases, and the denominator is unknown. This report does serve to highlight the urgent need for a population-based cancer registry in Meru County that collects and reports high quality data for policy, research, and planning of services.
Specific comments and questions:
The report refers to 'rates' and 'incidence' of various cancers, these should be correctly referred to
Shahin Sayed
Department of Pathology, Aga Khan University Hospital, Nairobi, Kenya Farrok Karsan Department of Oncology, Aga Khan University Hospital, Nairobi, Kenya This is an interesting study on hospice cancer data from Meru county in Kenya.
A few comments and observations:
The title should reflect that this is Hospice data. The methodological approach and conclusions are flawed specifically the fact that comparisons are being made with the Globocan estimates and the Kenya cancer registry data based solely on hospice data. As an example, stomach cancer by virtue of the nature of the disease and its late presentation at diagnosis is likely a hospice case whereas this is not generally true for prostate, cervix or breast cancer. There are too many generalizations; as an example, the year of admission is the same as the year of diagnosis. Also not convinced about the methodology used for assigning a diagnosis. Cancer registry data is based on a strict methodological approach to ascertain diagnosis from multiple sources. Using a hospice register may be too simplistic, I thought. However, in the absence of much data in the region, it is "interesting to know the ". So the paper may still be trends indexable but with modifications. Making general statements on trends but without the detailed comparison of Meru stats with Globocan stats. Authors can discuss the trends in what they have found. Pages 9-12 can be consolidated. Referencing and comparing their findings with that of Nairobi and Eldoret is probably more appropriate for trends rather than world stats.
The Discussion section on the various cancers can be further enriched by referencing local studies and published data. As an example the statement in the manuscript "While it is likely that majority of cervical cancers in Meru women are HPV-associated, further studies are needed to establish this" Do the authors expect cervical cancer etiology to be different from what is already an established fact? Was the intention to state that there may be regional differences in HPV genotypes? Some important work around prevalence and risk factors for certain cancers has already been published from Kenya and for others work is ongoing -this has not been mentioned in the manuscript-Some important work the authors may wish to reference include the following:
Human papillomavirus correlates of high-grade dysplasia in HIV-infected women in cervical Mombasa, : a cross-sectional analysis . Kenya 
Prevalence of Human Papillomavirus Genotypes among African Women with Normal Cervical
